IP Library › Granted Patent US 9,573,969
Granted Patent B2
US 9,573,969 · App. 14/851,249 · Granted Feb 21, 2017

Compounds and compositions as kinase inhibitors

Inventors: Matthew T. Burger (Cambridge, MA); Savithri Ramurthy (Cambridge, MA); Benjamin R. Taft (Emeryville, CA)
Assignee: NOVARTIS AG
C07F9/65583A61K31/675C07D213/74C07D403/12C07D413/04C07D413/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,573,969
App. No.
14/851,249
Granted
Feb 21, 2017
Kind
B2
Abstract

The present invention provides a compound of Formula I: wherein X, Y, Z, R 1 and R 2 are as described herein, and salts thereof and therapeutic uses of these compounds for treatment of disorders associated with RAF kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.

Claims (25)

1. A compound of formula I:

in which:

R 1 is selected from hydrogen and methyl;

R 2 is selected from pyridinyl and phenyl; wherein phenyl or pyridinyl can be substituted with a group selected from trifluoromethyl, 1,1-difluoroethyl and 2-fluoropropan-2-yl;

X and Y are independently selected from N and C—OCH 2 CHR 3 R 4 ; wherein R 3 is selected from hydrogen and OH; and R 4 is selected from 2-(phosphonooxy)methyl and phosphonooxy; with the proviso that if X is N, Y is C—OCH 2 CHR 3 R 4 ; and if Y is N, X is C—OCH 2 CHR 3 R 4 ; and

Z is selected from N and CH; or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 of formula Ia:

in which:

R 1 is selected from hydrogen and methyl;

R 2 is selected from pyridinyl and phenyl; wherein phenyl or pyridinyl can be substituted with a group selected from trifluoromethyl, 1,1-difluoroethyl and 2-fluoropropan-2-yl;

R 3 is selected from hydrogen and OH;

R 4 is selected from 2-(phosphonooxy)methyl and phosphonooxy; and

Z is selected from N and CH; or a pharmaceutically acceptable salt thereof.

3. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, selected from:

4. The compound of claim 1 of formula Ib:

in which:

R 1 is selected from hydrogen and methyl;

R 2 is selected from pyridinyl and phenyl; wherein phenyl or pyridinyl can be substituted with a group selected from trifluoromethyl, 1,1-difluoroethyl and 2-fluoropropan-2-yl;

R 3 is selected from hydrogen and OH;

R 4 selected from 2-(phosphonooxy)methyl and phosphonooxy; and

Z is selected from N and CH; or a pharmaceutically acceptable salt thereof.

5. The compound of claim 4 , or a pharmaceutically acceptable salt thereof, selected from:

6. A compound, or a pharmaceutically acceptable salt thereof, of formula:

7. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers.

8. A combination comprising a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof and one or more therapeutically active co-agents.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 23, 2015
From: BURGER, MATTHEW T.; RAMURTHY, SAVITHRI; TAFT, BENJAMIN R.
To: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Reel/Frame 037119/0969 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 23, 2015
From: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
To: NOVARTIS AG
Reel/Frame 037119/0989 →
Continuity (2)
Provisional Application 62049469 · Sep 12, 2014
Related Publication 20160075727A1 · Mar 17, 2016